肿瘤细胞治疗研究
ALL SOURCES
Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.
嵌合抗原受体（CAR）T 细胞疗法彻底改变了淋巴瘤和多发性骨髓瘤等血液系统恶性肿瘤的治疗。
Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A
Loncastuximab tesirine 在经重度治疗的 R/R DLBCL 中显示出具有临床意义的活性，包括 CAR-T 细胞治疗后的情形，血细胞减少常见但可控。汇总估计显示存在显著异质性，主要由真实世界队列驱动，应谨慎解读。
CAR-engineered cell therapies: current understandings and future perspectives.
嵌合抗原受体（CAR）工程化细胞疗法是免疫治疗领域的重大突破，最初应用于癌症，如今正拓展至多个临床领域。
Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease.
免疫检查点抑制剂已经改变了癌症治疗；然而，耐药性、靶向毒性和在自身免疫性疾病中有限的疗效推动了下一代免疫疗法的发展。
Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma.
尽管其取得了成功，但仍有约 60% 的患者治疗失败，这凸显出有必要更好地理解应答与耐药的决定因素。
Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells.
这些数据将 CAR19-GITRL-NK 细胞定位为一种有效的创新策略，将直接肿瘤靶向与主动破坏 Treg 驱动的免疫抑制结合起来，用于治疗 B 细胞白血病和淋巴瘤。
Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.
共纳入 18 项研究，涵盖 1400 余例患者。
Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR T Cells against Hematologic Malignancies.
我们的结果表明，靶向 PRC2 可能是增强 CAR T 细胞针对血液系统恶性肿瘤的功能性效应程序的一种有前景的方法。
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.
虽然嵌合抗原受体（CAR）T 细胞疗法可使复发性大 B 细胞淋巴瘤获得持久缓解，但持续性有限，长期应答的机制尚未完全阐明。
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.
头颈部鳞状细胞癌（HNSCC）仍是最具侵袭性的恶性肿瘤之一，治疗选择有限，尤其是在复发和转移性病例中。
MEMBER ACCOUNT
登录成功会直接打开下一页。
